Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

Palmqvist, Sebastian, Mattsson, Niklas, Hansson, Oskar, for the Alzheimer’s Disease Neuroimaging Initiative·2016·Brain

DOI 10.1093/brain/aww015

Cited by (400)

Items 101–200 of 400

Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease
Tengfei Guo, Deniz Korman, Renaud La Joie, Leslie M. J. Shaw, John Q. Trojanowski, William J. Jagust, Susan M. Landau, Alzheimer’s Disease Neuroimaging Initiative · 2020 · Alzheimer s Research & Therapy
Widespread distribution of tauopathy in preclinical Alzheimer's disease
Stephanie A. Schultz, Brian Andrew Gordon, Shruti Mishra, Yi Su, Richard J. Perrin, Nigel J. Cairns, John C. Morris, Beau M. Ances, Tammie L.S. Benzinger · 2018 · Neurobiology of Aging
Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
Eline A.J. Willemse, Betty Marije Tijms, Bart N.M. van Berckel, Nathalie Le Bastard, Wiesje M. van der Flier, Philip Scheltens, Charlotte Elisabeth Teunissen · 2021 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Lipids as Emerging Biomarkers in Neurodegenerative Diseases
Justin C. Wei, Li Chin Wong, Sebastian Boland · 2023 · International Journal of Molecular Sciences
Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease
Maxime Van Egroo, Justinas Narbutas, Daphné Chylinski, Pamela Villar González, Pierre Maquet, Éric Salmon, Christine Bastin, Fabienne Collette, Gilles Vandewalle · 2019 · SLEEP
Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly
Andreas Hahn, Tor Olof Strandberg, Erik Stomrud, Markus Nilsson, Danielle van Westen, Sebastian Palmqvist, Rik Ossenkoppele, Oskar Hansson · 2019 · Cerebral Cortex
Secondary prevention of Alzheimer’s dementia: neuroimaging contributions
Mara ten Kate, Silvia Ingala, Adam James Schwarz, Nick C. Fox, Gaël Chételat, Bart N.M. van Berckel, Michael Ewers, Christopher Foley, Juan Domingo Gispert, David Hill et al. · 2018 · Alzheimer s Research & Therapy
Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis
Antoine Leuzy, Irina Savitcheva, Konstantinos Chiotis, Johan Lilja, Pia Andersen, Nenad Bogdanović, Vesna Jelić, Agneta K. Nordberg · 2019 · European Journal of Nuclear Medicine and Molecular Imaging
Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals
Silvia Ingala, Jori Tomassen, Lyduine Eisa Collij, Naomi Prent, Dennis van ‘t Ent, Mara ten Kate, Elles Konijnenberg, Maqsood M. Yaqub, Philip Scheltens, Eco J. C. de Geus et al. · 2021 · Brain Communications
Fluid biomarkers in Alzheimer's disease
Simrén, Joel, Elmgren, Anders, Blennow, Kaj, Zetterberg, Henrik · 2023 · Advances in Clinical Chemistry
sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease
Davina Biel, Marc Suárez‐Calvet, Paul Hager, Anna Rubinski, Anna Dewenter, Anna Steward, Sebastian Niclas Roemer, Michael Ewers, Christian Haass, Matthias Brendel et al. · 2023 · EMBO Molecular Medicine
Neuropsychological Testing and Machine Learning Distinguish Alzheimer’s Disease from Other Causes for Cognitive Impairment
Gurevich, Pavel, Stuke, Hannes, Kastrup, Andreas, Stuke, Heiner, Hildebrandt, Helmut · 2017 · Frontiers in Aging Neuroscience
Age-related and amyloid-beta-independent tau deposition and its downstream effects
Anika Wuestefeld, Alexa Pichet Binette, David Berron, Nicola Spotorno, Danielle van Westen, Erik Stomrud, Niklas Mattsson, Olof T. Strandberg, Ruben A Smith, Sebastian Palmqvist et al. · 2023 · Brain
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
Arno de Wilde, Juhan Reimand, Charlotte Elisabeth Teunissen, Marissa Deborah Zwan, Albert D. Windhorst, Ronald Boellaard, Wiesje M. van der Flier, Philip Scheltens, Bart N.M. van Berckel, Femke H. Bouwman et al. · 2019 · Alzheimer s Research & Therapy
Clinical significance of fluid biomarkers in Alzheimer’s Disease
Piotr Lewczuk, Marta Łukaszewicz‐Zając, Piotr Mroczko, Johannes Kornhuber · 2020 · Pharmacological Reports
Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease
Alexandra N. Trelle, Valerie A. Carr, Edward N. Wilson, Michelle S. Swarovski, Madison P. Hunt, Tyler N. Toueg, Tammy Tran, Divya Channappa, Nicole K. Corso, Monica K. Thieu et al. · 2021 · Neurology
White matter hyperintensities are associated with subthreshold amyloid accumulation
Moscoso, Alexis, Rey-Bretal, David, Silva-Rodríguez, Jesús, Aldrey, Jose M., Cortés, Julia, Pías-Peleteiro, Juan, Ruibal, Álvaro, Aguiar, Pablo · 2020 · NeuroImage
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
Colin Groot, Ruben A Smith, Erik Stomrud, Alexa Pichet Binette, Antoine Leuzy, Anika Wuestefeld, Laura E.M. Wisse, Sebastian Palmqvist, Niklas Mattsson, Shorena Janelidze et al. · 2022 · Brain
Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults
Tengfei Guo, Leslie M. J. Shaw, John Q. Trojanowski, William J. Jagust, Susan M. Landau, Alzheimer’s Disease Neuroimaging Initiative · 2020 · Neurology
Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients
Christopher James Carswell, Zarni Win, Kirsty Muckle, Angus M Kennedy, Adam D. Waldman, Gemma Dawe, Tara D. Barwick, Sameer Khan, Paresh Malhotra, Richard J. Perry · 2017 · Journal of Neurology Neurosurgery & Psychiatry
Association of amyloid-β CSF/PET discordance and tau load 5 years later
Juhan Reimand, Lyduine Eisa Collij, Philip Scheltens, Femke H. Bouwman, Rik Ossenkoppele, Alzheimer’s Disease Neuroimaging Initiative · 2020 · Neurology
Astroglial activation and altered amyloid metabolism in human repetitive concussion
Pashtun Shahim, Yelverton Tegner, Niklas Marklund, Kina Höglund, Erik Portelius, David L. Brody, Kaj Blennow, Henrik Zetterberg · 2017 · Neurology
Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
Ashvini Keshavan, Henrietta Wellington, Zhongbo Chen, Ayesha Khatun, Miles D. Chapman, Melanie Hart, David M. Cash, William Coath, Thomas D. Parker, Sarah M. Buchanan et al. · 2021 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease
Lei Liu, Bianca M. Lauro, Amy He, Hyo Lee, Sanjay Bhattarai, Michael S. Wolfe, David Alan Bennett, Celeste M M. Karch, Tracy L. Young‐Pearse, Dominantly Inherited Alzheimer Network (DIAN) et al. · 2022 · Alzheimer s & Dementia
Preclinical Alzheimer’s disease biomarkers accurately predict cognitive and neuropathological outcomes
Justin M. Long, Dean W. Coble, Chengjie Xiong, Suzanne E. Schindler, Richard J. Perrin, Brian Andrew Gordon, Tammie L.S. Benzinger, Elizabeth Grant, Anne M. Fagan, Oscar Harari et al. · 2022 · Brain
Time between milestone events in the Alzheimer's disease amyloid cascade
Philip S. Insel, Michael Donohue, David Berron, Oskar Hansson, Niklas Mattsson · 2020 · NeuroImage
Amyloid-β PET—Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic
Ebba Gløersen Müller, Trine Holt Edwin, Caroline Stokke, Sigrid Stensby Navelsaker, Almira Babovic, Nenad Bogdanović, Anne‐Brita Knapskog, Mona Elisabeth Revheim · 2019 · PLoS ONE
Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults
ten Kate, Mara, Visser, Pieter Jelle, Bakardjian, Hovagim, Barkhof, Frederik, Sikkes, Sietske A. M., van der Flier, Wiesje M., Scheltens, Philip, Hampel, Harald, Habert, Marie-Odile, Dubois, Bruno et al. · 2018 · Frontiers in Aging Neuroscience
Biomarkers of blood–brain barrier and neurovascular unit integrity in human cognitive impairment and dementia
Scott R. French, Briana P. Meyer, Juan C. Arias, Swati Rane Levendovszky, Craig C Weinkauf · 2025 · Alzheimer s & Dementia
Brain myoinositol as a potential marker of amyloid-related pathology
Olga Voevodskaya, Konstantinos Poulakis, Pia C. Sundgren, Danielle van Westen, Sebastian Palmqvist, Lars‐Olof Wahlund, Erik Stomrud, Oskar Hansson, Eric Westman, for the Swedish BioFINDER Study Group et al. · 2019 · Neurology
Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers
Gemma Salvadó, Mahnaz Shekari, Carles Falcón, Grégory Operto, Marta Milà‐Alomà, Gonzalo Sánchez‐Benavides, Raffaele Cacciaglia, Eider M. Arenaza‐Urquijo, Aida Niñerola‐Baizán, Andrés Perissinotti et al. · 2022 · Brain Communications
Sleep disorders and Alzheimer’s disease pathophysiology: The role of the Glymphatic System. A scoping review
Kyriaki Astara, Alexandros Tsimpolis, Konstantinos Kalafatakis, George D. Vavougios, Georgia Xiromerisiou, Efthimios Dardiotis, George N. Christodoulou, Myrto T. Samara, Andreas S. Lappas · 2023 · Mechanisms of Ageing and Development
CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
François Mouton‐Liger, Julien Dumurgier, Emmanuel Cognat, Claire Hourrègue, Henrik Zetterberg, Hugo Vanderstichele, Eugeen Vanmechelen, Élodie Bouaziz-Amar, Kaj Blennow, Jacques Hugon et al. · 2020 · Alzheimer s Research & Therapy
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Enchi Liu, Dai Wang, Reisa Anne Sperling, Stephen Salloway, Nick C. Fox, Kaj Blennow, Philip Scheltens, Mark E. Schmidt, Johannes Rolf Streffer, Gerald Novak et al. · 2018 · Neurology
Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use
Theresa Köbe, Julie Gonneaud, Alexa Pichet Binette, Pierre‐François Meyer, Melissa McSweeney, Pedro Rosa‐Neto, John C.S. Breitner, Judes Poirier, Sylvia Villeneuve · 2020 · JAMA Network Open
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Dietmar Rudolf Thal, Koen Poesen, Rik R. Vandenberghe, Steffi De Meyer · 2025 · Molecular Neurodegeneration
Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
Alain D. Dekker, Juan Fortea, Rafael Blesa, Peter Paul De Deyn · 2017 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients
Christiana Bjorkli, Axel Sandvig, Ioanna Sandvig · 2020 · Frontiers in Aging Neuroscience
Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET
the Alzheimer’s Disease Neuroimaging Initiative, Yu Guo, Yuyuan Huang, Xue‐Ning Shen, Shi-Dong Chen, Hao Hu, Zuo-Teng Wang, Lan Tan, Jin‐Tai Yu · 2021 · Alzheimer s Research & Therapy
Nanoconstructs as a versatile tool for detection and diagnosis of Alzheimer biomarkers
Divya Gopalan, Abhijeet P. Pandey, Angel Treasa Alex, Guruprasad Kalthur, Sureshwar Pandey, N Udupa, Srinivas Mutalik · 2020 · Nanotechnology
Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity
Arianna Sala, Agneta K. Nordberg, Elena Rodriguez‐Vieitez, Alzheimer’s Disease Neuroimaging Initiative · 2020 · Molecular Psychiatry
Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: From biological biomarkers to clinical syndromes
Carandini, Tiziana, Arighi, Andrea, Sacchi, Luca, Fumagalli, Giorgio G., Pietroboni, Anna M., Ghezzi, Laura, Colombi, Annalisa, Scarioni, Marta, Fenoglio, Chiara, De Riz, Milena A. et al. · 2019 · Alzheimer's Research & Therapy
Clinical use of biomarkers in the era of Alzheimer's disease treatments
Lawren A. VandeVrede, Suzanne E. Schindler · 2024 · Alzheimer s & Dementia
Altered structural network organization in cognitively normal individuals with amyloid pathology
Olga Voevodskaya, Joana B. Pereira, Giovanni Volpe, Olof E. Lindberg, Erik Stomrud, Danielle van Westen, Eric Westman, Oskar Hansson · 2017 · Neurobiology of Aging
Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults
Mirian Ecay‐Torres, Ainara Estanga, Mikel Tainta, Andrea Izagirre, Maite García‐Sebastián, Jorge Villanúa, Montserrat Clerigué, Ane Iriondo, Iratxe Urreta, Arantzazu Arrospide et al. · 2018 · Neurology
Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
Betty Marije Tijms, Lisa Vermunt, Marissa Deborah Zwan, Argonde C. van Harten, Wiesje M. van der Flier, Charlotte Elisabeth Teunissen, Philip Scheltens, Pieter Jelle Visser, for ADNI · 2018 · Annals of Clinical and Translational Neurology
Deep-MEG: spatiotemporal CNN features and multiband ensemble classification for predicting the early signs of Alzheimer’s disease with magnetoencephalography
Antonio Giovannetti, Gianluca Susi, Paola Casti, Arianna Mencattini, Sandra Angelica Pusil, María Eugenia López, Corrado Di Natale, Eugenio Martinelli · 2021 · Neural Computing and Applications
Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort
Hyemin Jang, Ji Sun Kim, Hye Joo Lee, Chi‐Hun Kim, Duk Lyul Na, Hee Jin Kim, José Antonio Allué, Leticia Sarasa, Sergio Castillo, Pedro Pesini et al. · 2021 · Alzheimer s Research & Therapy
Sleep Biomarkers for Predicting Cognitive Decline and Alzheimer’s Disease: A Systematic Review of Longitudinal Studies
Matteo Carpi, Mariana Fernandes, Nicola Biagio Mercuri, Claudio Liguori · 2023 · Journal of Alzheimer s Disease
Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
Ellen Dicks, Lisa Vermunt, Wiesje M. van der Flier, Pieter Jelle Visser, Frederik Barkhof, Philip Scheltens, Betty Marije Tijms · 2019 · NeuroImage Clinical
Prognostic value of ATN Alzheimer biomarkers: 60‐month follow‐up results from the Argentine Alzheimer's Disease Neuroimaging Initiative
Ricardo Allegri, Patricio Chrem Méndez, Ismael Luis Calandri, Gabriela Cohen, María Martín, María Julieta Russo, Lucía Crivelli, Lucía Pertierra, Fernanda Tapajóz, María Florencia Clarens et al. · 2020 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease
Huanhuan Liu, Dandan Zhang, Huawei Lin, Qi Zhang, Ling Zheng, Yuxin Zheng, Xiaolong Yin, Zuanfang Li, Shengxiang Liang, Saie Huang · 2021 · Frontiers in Aging Neuroscience
Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model
Saffire Hanna Krance, Hugo Cogo‐Moreira, Jennifer S. Rabin, Sandra E. Black, Walter Swardfager · 2019 · Journal of Neuroscience
Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study
Hui-Fu Wang, Xue‐Ning Shen, Jieqiong Li, John Suckling, Chen‐Chen Tan, Yan‐Jiang Wang, Lei Feng, Can Martin Zhang, Lan Tan, Qiang Dong et al. · 2020 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins
Konstantin Yu. Kulichikhin, Sergei A. Fedotov, Maria S. Rubel, N. M. Zalutskaya, Anastasia E. Zobnina, Oksana A. Malikova, Н. Г. Незнанов, Yury O. Chernoff, Aleksandr A. Rubel · 2021 · Prion
Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice
Luisa Agnello, Caterina Maria Gambino, Anna Maria Ciaccio, Anna Masucci, Roberta Vassallo, Martina Tamburello, Concetta Scazzone, Bruna Lo Sasso, Marcello Ciaccio · 2024 · International Journal of Molecular Sciences
Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
Ronald Lautner, Philip S. Insel, Tobias Borgh Skillbäck, Bob Olsson, Mikael Landén, Giovanni Battista Frisoni, Sanna‐Kaisa Herukka, Harald Juergen Hampel, Anders Wallin, Lennart Minthon et al. · 2017 · Alzheimer s Research & Therapy
18F-florbetapir Positron Emission Tomography–determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery
Rebecca Y. Klinger, Olga G James, Salvador Borges‐Neto, Tiffany L. Bisanar, Yi‐Ju Li, Wenjing Qi, Miles Berger, Niccolò Terrando, Mark F. Newman, Pudugramam Murali Doraiswamy et al. · 2018 · Anesthesiology
Reduced brain amyloid burden in elderly patients with narcolepsy type 1
Audrey Gabelle, Isabelle Jaussent, Fayçal Ben Bouallègue, Sylvain Lehmann, Régis Lopez, Lucie Barateau, Caroline Grasselli, Carole Pesenti, Delphine de Verbizier, Séverine Béziat et al. · 2018 · Annals of Neurology
Sleep apnoeas may represent a reversible risk factor for amyloid-β pathology
Claudio Liguori, Agostino Chiaravalloti, Francesca Izzi, Marzia Nuccetelli, Sergio Bernardini, Orazio Schillaci, Nicola Biagio Mercuri, Fabio Placidi · 2017 · Brain
Amyloid Network Topology Characterizes the Progression of Alzheimer’s Disease During the Predementia Stages
Joana B. Pereira, Tor Olof Strandberg, Sebastian Palmqvist, Giovanni Volpe, Danielle van Westen, Eric Westman, Oskar Hansson, Alzheimer’s Disease Neuroimaging Initiative · 2017 · Cerebral Cortex
Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer’s Disease Pathology Between Three Independent Assay Platforms
James D. Doecke, Alan Rembach, Victor L. Villemagne, Shiji Varghese, Stephanie Ruth Rainey‐Smith, Shannon Sarros, Lisbeth Anne Evered, Christopher James Fowler, Kelly Kathleen Pertile, Rebecca L. Rumble et al. · 2017 · Journal of Alzheimer s Disease
Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits
Caroline Bouter, Jonathan S. Vogelgsang, Jens Wiltfang · 2019 · Clinica Chimica Acta
PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
Juhan Reimand, Arno de Wilde, Charlotte Elisabeth Teunissen, Marissa Deborah Zwan, Albert D. Windhorst, Ronald Boellaard, Frederik Barkhof, Wiesje M. van der Flier, Philip Scheltens, Bart N.M. van Berckel et al. · 2019 · Alzheimer s Research & Therapy
A panel of blood lipids associated with cognitive performance, brain atrophy, and Alzheimer's diagnosis: A longitudinal study of elders without dementia
Ya‐Hui Ma, Xue‐Ning Shen, Wei Xu, Yuyuan Huang, Hong‐Qi Li, Lin Tan, Chen‐Chen Tan, Qiang Dong, Lan Tan, Jin‐Tai Yu et al. · 2020 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer’s Disease Prior to Overt Global Amyloid Positivity
Doaa G. Ali, Ahmed Ali Bahrani, Justin M. Barber, Riham H. El Khouli, Brian T. Gold, Jordan P. Harp, Yang Jiang, Donna M. Wilcock, Gregory A. Jicha · 2022 · Journal of Alzheimer s Disease
A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation
Seung Hyun Kim, Min‐Young Noh, Hee-Jin Kim, Ki‐Wook Oh, Jinseok Park, Sang-Gon Lee, Yeonsil Moon, Young-Eun Kim, Jae Sung Bae, Hee Kyung Jin et al. · 2019 · Dementia and Neurocognitive Disorders
Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE ® system
Hisashi Nojima, Satoshi Itō, Akira Kushida, Aki Abe, Wataru Motsuchi, David Verbel, Manu Leen Jef Vandijck, Geert Jannes, Ina Vandenbroucke, Katsumi Aoyagi · 2022 · Annals of Clinical and Translational Neurology
Race modifies default mode connectivity in Alzheimer’s disease
Maria B. Misiura, Junjie Wu, Deqiang Qiu, Jennifer Christina Howell, Monica W. Parker, Jessica A. Turner, William T. Hu · 2020 · Translational Neurodegeneration
A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles
Samantha C. Burnham, Leonardo Iaccarino, Michael J. Pontecorvo, Adam Fleisher, Ming‐Chi Lu, Emily C. Collins, Michael D. Devous · 2023 · Brain Communications
Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials
Jesus Thomas Abanto, Alok Kumar Dwivedi, Bruno Pietro Imbimbo, Alberto Javier Espay · 2024 · Brain
Cerebrospinal Fluid Amyloid Beta, Tau Levels, Apolipoprotein, and 1H-MRS Brain Metabolites in Alzheimer's Disease: A Systematic Review
Albert Dayor Piersson, Mazlyfarina Mohamad, Fadilah Rajab, Subapriya Suppiah · 2020 · Academic Radiology
Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer’s continuum
Eun Hyun Seo, Ho Jae Lim, Hyung‐Jun Yoon, Kyu Yeong Choi, Jang Jae Lee, Jun Young Park, Seong Hye Choi, Hoowon Kim, Byeong Chae Kim, Kun Ho Lee · 2021 · Alzheimer s Research & Therapy
Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition
Hazal Ozlen, Alexa Pichet Binette, Theresa Köbe, Pierre‐François Meyer, Julie Gonneaud, Frédéric St‐Onge, Karine Provost, Jean‐Paul Soucy, Pedro Rosa‐Neto, John C.S. Breitner et al. · 2022 · JAMA Neurology
Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics
Ryan T. Muir, Zahinoor Ismail, Sandra E. Black, Eric Edward Smith · 2023 · Alzheimer s & Dementia
Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease
Francesco Panza, Vittorio Dibello, Rodolfo Sardone, Roberta Zupo, Fabio Castellana, Ivana Leccisotti, Maria Claudia Moretti, Mario Altamura, Antonello Bellomo, Antonio Daniele et al. · 2025 · Expert Opinion on Biological Therapy
CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort
Marco Spallazzi, Federica Barocco, Giovanni Michelini, Paolo Immovilli, Arens Taga, Nicola Morelli, Livia Ruffini, Paolo Caffarra · 2019 · Acta Neurologica Belgica
Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)
A. Chincarini, Enrico Peira, Silvia Daniela Morbelli, Matteo Pardini, Matteo Bauckneht, Javier Arbizu, Miguel S. Castelo-Branco, K. A. Büsing, Alexandre de Mendonça, Mira Didic et al. · 2019 · NeuroImage Clinical
The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment
Emma Borland, Erik Stomrud, Danielle van Westen, Oskar Hansson, Sebastian Palmqvist · 2020 · Alzheimer s Research & Therapy
Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
Oriol Grau‐Rivera, Irene Navalpotro‐Gómez, Gonzalo Sánchez‐Benavides, Marc Suárez‐Calvet, Marta Milà‐Alomà, Eider M. Arenaza‐Urquijo, Gemma Salvadó, Aleix Sala‐Vila, Mahnaz Shekari, José María Gónzalez‐de‐Echávarri et al. · 2021 · Alzheimer s Research & Therapy
Long-covid cognitive impairment: Cognitive assessment and apolipoprotein E (APOE) genotyping correlation in a Brazilian cohort
José Wagner Leonel Tavares-Júnior, Danilo Nunes Oliveira, Jean Breno Silveira da Silva, Werbety Lucas Queiroz Feitosa, Artur Victor Menezes Sousa, Letícia Chaves Vieira Cunha, Safira de Brito Gaspar, Carmem Meyve Pereira Gomes, Laís Lacerda Brasil de Oliveira, Caroline Aquino Moreira-Nunes et al. · 2022 · Frontiers in Psychiatry
Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting
Na‐Yeon Jung, Eun Soo Kim, Hyang-Sook Kim, Sumin Jeon, Myung Jun Lee, Kyoungjune Pak, Jae‐Hyeok Lee, Young Min Lee, Kangyoon Lee, Jin‐Hong Shin et al. · 2020 · Journal of Alzheimer s Disease
Amyloid and Tau in Alzheimer’s Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?
Anand Kumar, Charles B. Nemeroff, Joseph J. Cooper, Alik S. Widge, Carolyn I. Rodríguez, Linda L. Carpenter, William Maffitt McDonald · 2021 · American Journal of Psychiatry
Standardized Uptake Value Ratio-Independent Evaluation of Brain Amyloidosis
A. Chincarini, Francesco Sensi, L. Rei, Irene Bossert, Silvia Daniela Morbelli, Ugo Paolo Guerra, Giovanni Battista Frisoni, Alessandro Padovani, Flavio Mariano Nobili, Alzheimer’s Disease Neuroimaging Initiative · 2016 · Journal of Alzheimer s Disease
A blood-based signature of cerebrospinal fluid Aβ1–42 status
Benjamin Goudey, Bowen John Fung, Christine Schieber, Noel Garry Faux, Michael Walter Weiner, Paul S. S. Aisen, Ronald Carl Petersen, Clifford R. Jack, William J. Jagust, John Q. Trojanowki et al. · 2019 · Scientific Reports
Associations of Subsyndromal Symptomatic Depression with Cognitive Decline and Brain Atrophy in Elderly Individuals without Dementia: A Longitudinal Study
Zhao Zhang, Feng Wei, Xue‐Ning Shen, Ya‐Hui Ma, Keliang Chen, Qiang Dong, Lan Tan, Jin‐Tai Yu · 2020 · Journal of Affective Disorders
Tau pathology mediates age effects on medial temporal lobe structure
Laura E.M. Wisse, Long Xie, Sandhitsu R. Das, Robin de Florès, Oskar Hansson, Mohamad Habes, Jimit J. Doshi, Christos A. Davatzikos, Paul A. Yushkevich, David A. Wolk · 2021 · Neurobiology of Aging
Cerebrospinal fluid dynamics and discordant amyloid biomarkers
Jonathan Graff‐Radford, David Thomas Jones, Heather J. Wiste, Petrice M. Cogswell, Stephen D. Weigand, Val J. Lowe, Benjamin D. Elder, Prashanthi Vemuri, Argonde C. van Harten, Michelle M. Mielke et al. · 2021 · Neurobiology of Aging
Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
Ashvini Keshavan, Henrietta Wellington, Zhongbo Chen, Ayesha Khatun, Miles D. Chapman, Melanie Hart, David M. Cash, William Coath, Thomas D. Parker, Sarah M. Buchanan et al. · 2020 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease
Emelie Andersson, Nina Schultz, Takashi Saito, Takaomi C. Saido, Kaj Blennow, Gunnar K. Gouras, Henrik Zetterberg, Oskar Hansson · 2023 · Alzheimer s Research & Therapy
Altered Nucleus Basalis Connectivity Predicts Treatment Response in Mild Cognitive Impairment
Dewen Meng, Xingfeng Li, Markus Bauer, John‐Paul Taylor, Dorothee P. Auer, Alzheimer’s Disease Neuroimaging Initiative · 2018 · Radiology
Cerebrospinal Fluid Levels of β-Amyloid 40 and β-Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients
Hyun Jae Kim, Tae Sung Lim, Sun Min Lee, Tae-Sung Kim, Youngbin Kim, Young‐Sil An, Young Chul Youn, Sun Ah Park, Jaerak Chang, So Young Moon · 2019 · Journal of Clinical Neurology
The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status
Miriam Thiel Ashford, Dallas P. Veitch, John M Neuhaus, Rachel L. Nosheny, Duygu Tosun, Michael Walter Weiner · 2021 · Alzheimer s & Dementia
Dynamics of neuroinflammation in Alzheimer's disease
Denis Smirnov, Douglas Galasko · 2022 · The Lancet Neurology
Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk
Muhammad Ali, Yun Ju Sung, Fengxian Wang, María Victoria Fernández, John C. Morris, Anne M. Fagan, Kaj Blennow, Henrik Zetterberg, Amanda Heslegrave, Per Johansson et al. · 2022 · PLoS ONE
Impact of Resilience on the Association Between Amyloid-β and Longitudinal Cognitive Decline in Cognitively Healthy Older Adults
Dominik Georg Friedrich Wolf, Alzheimer’s Disease Neuroimaging Initiative, Florian U. Fischer, Andreas Fellgiebel · 2019 · Journal of Alzheimer s Disease
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yixuan Yang, Lina Qiu · 2024 · Brain Sciences
Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer
Marta Milà‐Alomà, Gemma Salvadó, Mahnaz Shekari, Oriol Grau‐Rivera, Aleix Sala‐Vila, Gonzalo Sánchez‐Benavides, Eider M. Arenaza‐Urquijo, José María Gónzalez‐de‐Echávarri, Maryline Simon, Gwendlyn Kollmorgen et al. · 2021 · The Journal of Prevention of Alzheimer s Disease
Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer’s dementia: a comparison of methods
Alzheimer’s Disease Neuroimaging Initiative, A Sörensen, Ganna Blazhenets, Florian Schiller, Philipp Tobias Meyer, Lars Frings · 2020 · Alzheimer s Research & Therapy
Establishment of combined diagnostic models of Alzheimer’s disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS)
Dong‐Yu Fan, Jie-Ming Jian, Shan Huang, Weiwei Li, Ying‐Ying Shen, Zhen Wang, Gui‐Hua Zeng, Xu Yi, Wang‐Sheng Jin, Yu-Hui Liu et al. · 2022 · Translational Psychiatry